Suppression of Autoimmune Retinal Inflammation by an Antiangiogenic Drug

Takeru Yoshimura, Ofra Benny*, Lauren Bazinet, Robert J. D'Amato

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Chronic and recurrent uveitis account for approximately 10% of legal blindness in the western world. Autoimmune uveitis is driven by activated CD4+ T cells that differentiate into effector T helper cells (Th1, Th2, and Th17) which release proinflammatory cytokines that damage the retina. In this study we investigated the effect of the methionine aminopeptidase 2 (MetAP2) inhibitor, Lodamin, on T cell activation and differentiation. MetAp2 is an enzyme which regulates cellular protein synthesis and is highly expressed in T cells. Lodamin was found to suppress T cell receptor (TCR) mediated T cell proliferation and reduced the production of Th1 and Th17 cells. Further, Lodamin suppressed overall inflammation in the mouse model of experimental autoimmune uveitis (EAU) by a six fold. This effect was attributed in part to a reduction in retinal proinflammatory cytokines, down regulation of MetAP2 expression in purified lymph node CD4+ T cells, and a general normalization of the systemic immune reaction.

Original languageAmerican English
Article numbere66219
JournalPLoS ONE
Issue number6
StatePublished - 13 Jun 2013
Externally publishedYes


Dive into the research topics of 'Suppression of Autoimmune Retinal Inflammation by an Antiangiogenic Drug'. Together they form a unique fingerprint.

Cite this